Cidara Therapeutics Inc. (CDTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 6310 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments32,73159,68035,91250,26874,56275,314
Cash and cash equivalents32,73159,68035,91250,26874,56260,813
Short-term investments      14,501
Restricted cash and investments  2,5937,03710,000  
Receivables5,8335,35611,175  321
Inventory, net of allowances, customer advances and progress billings      
Inventory      
Other undisclosed current assets6,5304,0693,0675,5462,5672,035
Total current assets:45,09471,69857,19165,81477,12977,670
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization    
Operating lease, right-of-use asset1,2052,2878681,632
Property, plant and equipment2222563424297121,044
Other noncurrent assets1,0721,0842,0231,1011,271321
Total noncurrent assets:2,4993,6273,2333,1621,9831,365
TOTAL ASSETS:47,59375,32560,42468,97679,11279,035
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,11916,35816,7379,6139,5539,418
Employee-related liabilities4,8594,2103,6582,8242,571
Accounts payable1,4471,3014,5681,8872,8462,590
Accrued liabilities7,67210,1987,9594,0683,8834,257
Debt 2,5917,02310,7839,9282,667
Derivative instruments and hedges, liabilities     411 
Other undisclosed current liabilities20,85315,06814,8049,803  
Total current liabilities:29,97234,01738,56430,19919,89212,085
Noncurrent Liabilities
Long-term debt and lease obligation 1,322 942  
Finance lease, liability    
Liabilities, other than long-term debt    81 
Other liabilities     81 
Operating lease, liability 1,322 942
Other undisclosed noncurrent liabilities20,52517,09111,145  7,206
Total noncurrent liabilities:20,52519,73511,145942817,206
Total liabilities:50,49753,75249,70931,14119,97319,291
Equity
Equity, attributable to parent(2,904)21,57310,71537,83559,13959,744
Common stock774332
Additional paid in capital404,055398,733345,411297,659277,871209,140
Accumulated other comprehensive loss      (8)
Accumulated deficit(406,966)(377,167)(334,700)(259,827)(218,735)(149,390)
Total equity:(2,904)21,57310,71537,83559,13959,744
TOTAL LIABILITIES AND EQUITY:47,59375,32560,42468,97679,11279,035

Income Statement (P&L) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues      
Gross profit:      
Operating expenses(94,006)(91,827)(83,916)(62,639)(63,285)(55,721)
Other undisclosed operating income 64,28849,57212,06720,915  
Operating loss:(29,718)(42,255)(71,849)(41,724)(63,285)(55,721)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
191(212)(262)6324,269(7)
Interest and debt expense (2)(12)(5)(8)(13)(18)
Loss from continuing operations before equity method investments, income taxes:(29,529)(42,479)(72,116)(41,100)(59,029)(55,746)
Other undisclosed income from continuing operations before income taxes 2     
Loss from continuing operations before income taxes:(29,527)(42,479)(72,116)(41,100)(59,029)(55,746)
Income tax expense(272)     
Loss from continuing operations:(29,799)(42,479)(72,116)(41,100)(59,029)(55,746)
Loss before gain (loss) on sale of properties:(42,479)(72,116)(41,100)(59,029)(55,746)
Net loss:(29,799)(42,479)(72,116)(41,100)(59,029)(55,746)
Other undisclosed net income attributable to parent  12581318
Net loss attributable to parent:(29,799)(42,467)(72,111)(41,092)(59,016)(55,728)
Preferred stock dividends and other adjustments   (2,762) (10,329) 
Net loss available to common stockholders, diluted:(29,799)(42,467)(74,873)(41,092)(69,345)(55,728)

Comprehensive Income ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(29,799)(42,479)(72,116)(41,100)(59,029)(55,746)
Comprehensive loss:(29,799)(42,479)(72,116)(41,100)(59,029)(55,746)
Other undisclosed comprehensive income, net of tax, attributable to parent  12582111
Comprehensive loss, net of tax, attributable to parent:(29,799)(42,467)(72,111)(41,092)(59,008)(55,735)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: